🇺🇸 OCTAPLAS in United States

27 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Dyspnoea — 4 reports (14.81%)
  2. Hypotension — 4 reports (14.81%)
  3. Shock — 4 reports (14.81%)
  4. Nausea — 3 reports (11.11%)
  5. Anaphylactic Reaction — 2 reports (7.41%)
  6. Blood Pressure Decreased — 2 reports (7.41%)
  7. Cardiac Arrest — 2 reports (7.41%)
  8. Fatigue — 2 reports (7.41%)
  9. Pyrexia — 2 reports (7.41%)
  10. Restlessness — 2 reports (7.41%)

Source database →

OCTAPLAS in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is OCTAPLAS approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for OCTAPLAS in United States?

University College, London is the originator. The local marketing authorisation holder may differ — check the official source linked above.